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Abstract
Background: Guidelines for assessing methodological and reporting quality of systematic reviews (SRs) were
developed to contribute to implementing evidence-based health care and the reduction of research waste. As SRs
assessing a cohort of SRs is becoming more prevalent in the literature and with the increased uptake of SR
evidence for decision-making, methodological quality and standard of reporting of SRs is of interest. The objective
of this study is to evaluate SR adherence to the Quality of Reporting of Meta-analyses (QUOROM) and PRISMA
reporting guidelines and the A Measurement Tool to Assess Systematic Reviews (AMSTAR) and Overview Quality
Assessment Questionnaire (OQAQ) quality assessment tools as evaluated in methodological overviews.
Methods: The Cochrane Library, MEDLINE®, and EMBASE® databases were searched from January 1990 to October
2014. Title and abstract screening and full-text screening were conducted independently by two reviewers. Reports
assessing the quality or reporting of a cohort of SRs of interventions using PRISMA, QUOROM, OQAQ, or AMSTAR
were included. All results are reported as frequencies and percentages of reports and SRs respectively.
Results: Of the 20,765 independent records retrieved from electronic searching, 1189 reports were reviewed for
eligibility at full text, of which 56 reports (5371 SRs in total) evaluating the PRISMA, QUOROM, AMSTAR, and/or
OQAQ tools were included. Notable items include the following: of the SRs using PRISMA, over 85% (1532/1741)
provided a rationale for the review and less than 6% (102/1741) provided protocol information. For reports using
QUOROM, only 9% (40/449) of SRs provided a trial flow diagram. However, 90% (402/449) described the explicit
clinical problem and review rationale in the introduction section. Of reports using AMSTAR, 30% (534/1794) used
duplicate study selection and data extraction. Conversely, 80% (1439/1794) of SRs provided study characteristics of
included studies. In terms of OQAQ, 37% (499/1367) of the SRs assessed risk of bias (validity) in the included studies,
while 80% (1112/1387) reported the criteria for study selection.
Conclusions: Although reporting guidelines and quality assessment tools exist, reporting and methodological
quality of SRs are inconsistent. Mechanisms to improve adherence to established reporting guidelines and
methodological assessment tools are needed to improve the quality of SRs.
Keywords: Reporting quality, Methodological quality, Systematic reviews, Guideline adherence
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Background
Systematic reviews (SRs) are considered the gold stand-
ard for evidence used to evaluate the benefits and harms
of healthcare interventions. They are powerful tools used
to assess treatment effectiveness which can subsequently
improve patient care [1]. SR evidence has become in-
creasingly important in clinical decision-making and for
informing clinical guidelines and health policy [2, 3].
Often, the quality of both methodology and reporting
of SRs is flawed due to deficiencies in the design, con-
duct, and reporting. Poorly conducted SRs can lead to
inaccurate estimates of treatment effectiveness, mislead-
ing conclusions, and reduced applicability, all of which
are a waste of limited resources [4]. Unfortunately,
poorly conducted or reported SRs may be associated
with bias, limiting their usefulness [5]. When SRs com-
ply with established methodology, report findings trans-
parently, and are free of bias, they provide relevant
information for practice guideline developers and other
stakeholders such as policy makers [5]. As such, SR
methodologists have proposed and developed various
methodological and reporting guidelines over the years
to assist in improving the methodological rigor and
reporting of SRs.
With the rise of evidence-based medicine, criteria for
assessing quality began to emerge, such as Mulrow [6]
and Sacks [7]. In 1991, Oxman and Guyatt developed the
Overview Quality Assessment Questionnaire (OQAQ) [8],
a validated tool to assess methodological quality for SRs of
intervention studies. Since then, SR methodologists have
suggested several other methodological quality (MQ)
items, such as potential sources of bias, as important in
improving quality of conduct. A Measurement Tool to
Assess Systematic Reviews (AMSTAR) [9] tool was devel-
oped in 2007 for SRs for intervention studies to include
these additional items. In 2010, a revised tool (R-
AMSTAR) was developed to provide a quantitative scor-
ing method to assess quality [10]. The accurate reporting
of methods and SR findings was established in the late
1990s. In 1999, the Quality of Reporting of Meta-analyses
(QUOROM) Statement was developed to evaluate the
completeness of reporting of meta-analyses of randomized
trials [11]. A decade later, the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
Statement was developed as an update of QUOROM to
address several conceptual and methodological advances
in the conduct and reporting of SRs of randomized trial
[12]. In 2011, Cochrane developed the Methodological
Expectations of Cochrane Intervention Reviews (MECIR)
guidelines to specify the methodological and reporting
standards for Cochrane intervention protocols and re-
views [13, 14]. These guidelines drew criteria from
AMSTAR, PRISMA, and other guidelines from organiza-
tions such as the US Institute of Medicine [13, 14].
Little was known about how quality or reporting of SRs
was assessed in methodological reports. In a separate
manuscript, we mapped the methods used to assess SR
quality (e.g., use of quality assessment tools) or reporting
of SRs (e.g., reporting guidelines) in methodological
reports [15]. We found that the criteria used to assess MQ
and reporting quality (RQ) of SRs varied considerably.
These findings raised an important issue regarding how
well SR authors used published reporting guidelines and
MQ assessment tools.
Although methodological studies of SRs assessing the
MQ or RQ have been published, adherence of SRs to
established MQ and RQ assessment tools is unknown.
We will address this aspect by examining existing meth-
odological overviews.
Objectives
The objective of this study was to determine SR adher-
ence to the QUOROM and PRISMA reporting guide-
lines and the AMSTAR and OQAQ quality assessment
tools as evaluated in methodological overviews.
Methods
Definitions and important concepts
SRs and meta-analyses were defined based on the guide-
lines provided by the Cochrane Collaboration and the
PRISMA Statement [12, 16]. We adopted the term over-
view to mean a summary of evidence from more than
one SR at a variety of different levels, including the com-
bination of different interventions, different outcomes,
different conditions, problems or populations, or the
provision of a summary of evidence on the adverse
events of an intervention [17, 18]. Other terminology
used to describe overviews includes systematic review of
systematic reviews, reviews of reviews, or an umbrella re-
view. We included publications that are “methodological
overviews,” meaning research that has assessed the MQ
or RQ of a cohort of SRs and refer to these publications
simply as “reports.”
Methodological quality and completeness of reporting
There is an important distinction between SR quality of
methods and quality of reporting. MQ is concerned with
how well a SR was designed and conducted (e.g., litera-
ture search, selection criteria, pooling of data). RQ refers
to how well methodology and findings were described in
the SR report(s) [19]. This critical difference should be
reflected in the choice of quality assessment tools and
reporting guidelines.
Eligibility criteria
Inclusion criteria
This work stems from a parallel investigation where any
methodological report published between January 1990
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and October 2014 with a primary objective to assess the
quality of methodology, reporting, or other quality char-
acteristics of SRs was included [15]. We included only
those methodological reports that evaluated SRs ad-
dressing the comparative effectiveness of interventions
as most quality tools have been developed for interven-
tion reviews. For this paper, however, we include only
those reports using the most frequently employed pub-
lished MQ (AMSTAR and OQAQ) and RQ (PRISMA
and QUOROM) tools, as determined from the parallel
investigation [15].
Exclusion criteria
We excluded reports of clinical interventions, where the
intent was to summarize the evidence for use in health-
care decision-making; reports assessing the quality of
diagnostic, screening, etiological, or prognostic studies;
and other publication types, such as editorials, narrative
reviews, rapid reviews, and network meta-analyses. Re-
views that include study designs other than randomized
controlled trials were also excluded. Reports in lan-
guages other than English were not included. Reports in-
cluding fewer than 10 SRs, assessing the reliability of an
assessment tool, evaluating only one methodological
characteristic (e.g., search strategy), or those assessing
only SRs with pooled estimates of effect were also
excluded.
Search methods
An experienced information specialist developed and
conducted an extensive search of the Cochrane Library,
EMBASE®, and MEDLINE® to identify methodological
reports published between January 1990 and October 16,
2014. Potentially eligible titles and/or abstracts were
identified using a combination of subject headings (e.g.,
“Meta-Analysis as Topic,” “Quality Control,” “Checklist”)
and key words (e.g., “umbrella review,” scoring, compli-
ance) (see Additional File 1). The search strategy was
peer-reviewed prior to execution [20]. Additional reports
eligible for inclusion were identified by members of the
research team prior to the start of the project [2, 21, 22].
These articles were used as “seed” articles when develop-
ing the electronic search strategy.
Screening
Titles and abstracts were screened for potentially rele-
vant articles using a liberal accelerated approach (i.e.,
any potentially relevant citations were identified by one
reviewer; a second person verified potential excludes).
Full-text screening was completed independently and in
duplicate by a team of reviewers with experience in
methodological reviews; a 5% pilot testing was con-
ducted at both screening levels. All screening disagree-
ments were discussed among pairs of reviewers, with
any outstanding disagreements resolved by an independ-
ent third reviewer (DM). A data management software,
DistillerSR® [23], was used to manage retrieved records,
screen citations/reports, record reasons for exclusion,
and store extracted data.
Data extraction
We developed standardized forms for data extraction of
items of interest from the included reports. Basic charac-
teristics and findings relating to the SRs that were
reviewed were extracted from each included report by
two of four reviewers; a 10% random sample of reports
was assessed for accuracy. A pre-extraction meeting was
held for all extraction levels along with pilot testing to
ensure consistency across reviewers. The following basic
characteristics of the included overviews were extracted:
year of publication, number of included SRs, specified
medical area, number of databases searched, language
restrictions, SR definition, types of publishing journals,
Cochrane or non-Cochrane review, reporting of avail-
ability of study protocol, and source of funding. Add-
itional items pertaining to the evaluated reviews were
extracted: intent of assessment (whether MQ or RQ),
the method(s) used to assess MQ or RQ, and details of
adherence of SRs to individual items included in OQAQ,
AMSTAR, QUOROM, or PRISMA guidelines.
Analyses
Summary statistics are reported as frequency and per-
centage of reports for report characteristics or frequency
and percentage of compliant SRs. No formal inferential
statistical analyses were conducted. In some cases, re-
ports would allocate points, or scores, to MQ or RQ
items. In these cases, we considered full points or a
complete score to be optimal; any meeting partial scores
would be considered non-adherent. A post hoc decision
was made to look at publications by their intent to as-
sess MQ only, RQ only, or both MQ and RQ. This deci-
sion was made without prior examination of the data by
the senior investigator (DM). Due to the limited number
of Cochrane reviews, the data did not allow for compari-
son of reports, including Cochrane versus non-Cochrane
reviews, as planned. This study was not registered in
PROSPERO or elsewhere as no known repositories take
methodological protocols. However, the study protocol
is available upon request.
Results
Of the 20,765 independent records retrieved from elec-
tronic searching, 1189 reports were reviewed in relation
to a subset of the eligibility at full text, of which 935
were excluded for either not assessing a cohort of SRs or
the primary intent was not to assess MQ or RQ. A sec-
ondary full-text review of the remaining 254 reports was
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carried out to determine whether exclusion criteria were
met; 178 reports were excluded, leaving 76 potentially
eligible reports. Once it was determined by the parallel
investigation [15] which quality tools were used most
often (OQAQ, AMSTAR, QUOROM, or PRISMA), 20
of the 76 reports were excluded for not using one of
those tools. The tools or criteria used by the 20 reports
were reported in a separate manuscript [15]. A total of
56 reports [21–77] evaluating 5371 SRs were included
(Fig. 1).
Report characteristics
The report characteristics are listed in Table 1. The ma-
jority of reports were conducted with the intent to assess
MQ or RQ using an appropriate tool; 61% (34/56) of re-
ports had a primary intent to assess MQ only, 7% (4/56)
reported having a primary intent to assess RQ, and 27%
(15/56) had a primary intent to assess both MQ and RQ.
The remaining reports did not use the tools according
to their intended use: one report used OQAQ for RQ as-
sessment, one used PRISMA for both RQ and MQ as-
sessments, and two reports used MQ tools to assess
both MQ and RQ. Regardless of intent, 27 reports used
AMSTAR, 26 reports used OQAQ, 13 reports used
PRISMA, and seven reports used QUOROM.
Reports spanned an 18-year period, of which 63% (35/
56) were published between 2010 and 2014, indicating a
marked increase in recent years. A median of 57 SRs
(interquartile range 30 to 109) were assessed in reports.
Almost all reports (91%) addressed SRs of a topic within
a specific medical field. Forty-three percent (24/56) of
reports include SRs limited to specific journals, half (28/
56) included SRs from a general sample of reviews
across medical journals, and only 7% (4/56) evaluated a
cohort of Cochrane reviews (i.e., from one specific
source). Accordingly, the majority of reports provided
details for the source of SRs, whether it was databases or
specific journals. Information as to whether language re-
strictions were used was provided in 61% (34/56) of re-
ports. In relation to specifying a definition for SR, 21%
(12/56) did not report this information. The majority of
reports (88%) did not state whether a protocol was avail-
able. Thirty-eight percent (21/56) of reports did not state
the source of funding for their research. Table 1 also de-
tails these characteristics according to reports using a
particular tool.
Adherence to MQ and RQ items in methodological
reports
The reports assessed adherence to items for the most
frequently used MQ and RQ tools (i.e., AMSTAR,
OQAQ, QUOROM, PRISMA). These data have been
collated across the samples of SRs (Tables 2, 3, 4, and 5).
Data pertaining to adherence to quality or reporting
criteria by item were obtainable from most methodo-
logical reports: 100% (13/13) using PRISMA, 71% or
more (5–6 out of 7, depending on the item) using
QUOROM, 85% or more (22–23 out of 27, depending
on the item) using AMSTAR, and 85% (22/26) using
OQAQ.
Adherence to reporting guidelines (RQ)
A total of 1741 SRs were included in the 13 reports that
used PRISMA (Table 2). Over 85% of SRs fully reported
their title, provided a rationale for the review, described
all information sources, and provided a general inter-
pretation of the results. However, compliance was poor
for several items, with only 38% (657/1741) of SRs speci-
fying any assessment of risk of bias methods across stud-
ies, 30% (527/1736) presenting results of risk of bias
assessments across studies, and 37% (647/1741) describ-
ing sources of funding. Less than 6% (102/1741) provide
protocol information in their SR report.
Six reports evaluating 449 SRs used QUOROM
(Table 3). One additional report did not provide any in-
formation by item and is excluded from the analysis.
Thirty percent (133/449) identified the report as a sys-
tematic review, and 9% (40/449) of SRs provided a figure
summarizing trial flow. Included SRs adhered well to
several QUOROM items. Over 85% of SRs used a struc-
tured format in the abstract, described the main results
in the abstract, provided an explicit clinical question and
rationale in the introduction/background section, de-
scribed the study selection criteria, and presented de-
scriptive data for each trial.
Adherence according to methodological quality
A total of 1794 SRs were included in the 23 reports that
provided AMSTAR assessments by item (Table 4).
Eighty percent (1439/1794) of SRs provided the charac-
teristics of included studies. Just over half (995/1794)
assessed publication bias. Thirty-nine percent (685/
1779) stated a conflict of interest, and a third (590/1794)
of SRs reported limitations. In addition, 30% (534/1794)
of SRs used duplicate study selection and data extraction
during the data collection process and 30% (537/1779)
provided a list of included and excluded studies.
Twenty-two reports evaluating 1387 SRs used the
OQAQ criteria (Table 5). Thirty-seven percent (499/
1367) of the SRs assessed risk of bias (validity) in the in-
cluded studies. Comparatively, 80% (1112/1387) of the
SRs reported the criteria for study selection, 75% (1027/
1387) of SRs reported search methods used to find the
evidence, 73% (1005/1387) described the methods used
to combine the findings, and 78% (1076/1387) of SRs de-
termined whether the conclusions were supported by
the data.
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Discussion
Previously, we identified that the most commonly used
tools or guidelines for critical appraisal and RQ assess-
ment were QUOROM, PRISMA, AMSTAR, and OQAQ
[15]. In this study, we evaluated SR, MQ, or RQ adher-
ence to these quality assessments or reporting guidelines
tools across methodological reports published between
1990 and 2014.
Our results indicate that SR adherence to reporting
items was variable. Over 85% provided a rationale for
the review when assessed using PRISMA, yet less than
6% gave protocol information in their SR report. Our
study, like others, shows that reporting of review proto-
cols is poorly reported [2, 24]. Review protocols are im-
portant to reduce duplication of research, allow
researchers to plan and anticipate potential issues, assess
validity of methods and replication of the review if de-
sired, and prevent arbitrary decision-making [78, 79]. In
addition, risk of bias across individual studies within re-
views, additional analyses, and funding source were also
poorly reported. These findings are consistent with other
research [24]. We note that compliance to some report-
ing criteria has improved over time. Nine percent pro-
vided a trial flow diagram as reported using the
QUOROM guidelines, compared to 63% using the
PRISMA guidelines. This observed improvement in
reporting could be partly due to journal endorsement of
the reporting guideline but also due to authors’ exposure
to the published tools or their general awareness to the
issues of reporting in health research over time. For the
few items that are similar between PRISMA and
QUOROM and show a lower compliance with PRISMA,
20,765 
independent reports 
retrieved from 
database searching 
20,765
Titles and abstracts 
screened
1189
Full text reports 
reviewed 
254
Full texts 
re-reviewed
76
Reports assessing the methodological 
and, or reporting quality of SRs
19,576 Excluded
935 Excluded, reasons:
726 did not assess a cohort
of SRs
209 primary intent was not to 
assess SR methodological or 
reporting quality
178 Excluded, reasons:
37 primary intent was not to assess SR methodological or 
reporting quality
12 did not assess a cohort of SRs
13 reports assessed a cohort of fewer than ten SRs
30 reports were abstracts or editorials
10 reports of texts were not available
12 reports were not available in English
3 reports were assessing non-human studies
22 reports assessed only one methods or reporting element 
(i.e. publication bias, or search strategy)
10 reports aimed to assess the validity of an assessment tool
29 reports only assessed meta-analyses, network meta-
analyses, etiological reviews, diagnostic reviews, reviews 
including observational studies
27 reports used AMSTAR to 
assess SR quality
7 reports used QUOROM to 
assess SR quality
13 reports used PRISMA to 
assess SR quality
20 reports which did not assess 
‘quality’ using PRISMA, 
QUOROM, AMSTAR or OQAQ 
were not included
56 
reports using one at least one of the 
tools below 
26 reports used OQAQ to 
assess SR quality
Fig. 1 Flow of study reports
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Table 2 Summary across reports of systematic reviews adhering to PRISMA reporting guidelines (N = 13)
Item assessed Item description No. of reports reporting
adherence by item
Adhering
SRs
Total
SRs
%
1. Title Identify the report as a systematic review, meta-analysis,
or both
13 1480 1741 85
2. Abstract: structured summary Provide a structured summary including the following
as applicable: background; objectives; data sources;
study eligibility criteria, participants, and interventions;
study appraisal and synthesis methods; results;
limitations; conclusions and implications of key findings;
systematic review registration number
13 885 1741 51
3. Introduction: rationale Describe the rationale for the review in the context of
what is already known
13 1532 1741 88
4. Objectives Provide an explicit statement of questions being
addressed with reference to participants, interventions,
comparisons, outcomes, and study design (PICOS)
13 1039 1741 60
5. Methods: protocol and registration Indicate if a review protocol exists, if and where it can
be accessed (e.g., web address), and, if available,
provide registration information including registration
number
13 102 1741 6
6. Eligibility criteria Specify study characteristics (e.g., PICOS, length of
follow-up) and report characteristics (e.g., years
considered, language, publication status) used as
criteria for eligibility, giving rationale
13 1342 1741 77
7. Information sources Describe all information sources (e.g., databases with
dates of coverage, contact with study authors to
identify additional studies) in the search and date last
searched
13 1530 1741 88
8. Search Present full electronic search strategy for at least one
database, including any limits used, such that it could
be repeated
13 923 1741 53
9. Study selection State the process for selecting studies (i.e., screening,
eligibility, included in systematic review, and, if
applicable, included in the meta-analysis)
13 1048 1741 60
10. Data collection process Describe method of data extraction from reports (e.g.,
piloted forms, independently, in duplicate) and any
processes for obtaining and confirming data from
investigators
13 1059 1741 61
11. Data items List and define all variables for which data were sought
(e.g., PICOS, funding sources) and any assumptions and
simplifications made
13 865 1741 50
12. Risk of bias in individual studies Describe methods used for assessing risk of bias of
individual studies (including specification of whether
this was done at the study or outcome level) and how
this information is to be used in any data synthesis
13 1251 1741 72
13. Summary measures State the principal summary measures (e.g., risk ratio,
difference in means)
13 1353 1741 78
14. Synthesis of results Describe the methods of handling data and combining
results of studies, if done, including measures of
consistency (e.g., I2) for each meta-analysis
13 1129 1736 65
15. Risk of bias across studies Specify any assessment of risk of bias that may affect
the cumulative evidence (e.g., publication bias, selective
reporting within studies)
13 657 1741 38
16. Additional analyses Describe methods of additional analyses (e.g., sensitivity
or subgroup analyses, meta-regression), if done, indicating
which were pre-specified
13 879 1738 51
17. Results: study selection Give numbers of studies screened, assessed for
eligibility, and included in the review, with reasons for
exclusions at each stage, ideally with a flow diagram
13 1094 1740 63
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these results are possibly attributed to differences in
operationalization of the criteria or simply as chance
findings.
Adherence to methodological quality items was also
variable. Overall, SRs using OQAQ adhered quite well to
all methodological items in the tool. OQAQ was vali-
dated and is well accepted, but it was developed and val-
idated over two decades ago [8]. The OQAQ criteria do
not include assessment of issues such as a priori design,
assessment of publication bias, and conflict of interest.
As such, OQAQ differs from AMSTAR, which was pub-
lished and validated more recently [80, 81]. For the 27
reports using AMSTAR to assess quality of SRs, the per-
centage of SRs meeting AMSTAR criteria was mediocre.
One third or less of SRs used duplicate study selection
and data extraction, provided a list of included and ex-
cluded studies within their review, or reported limitations.
One small study has also shown the need for better adher-
ence to AMSTAR [82]. We would expect that future re-
search will include an evaluation of the recently published
risk of bias in systematic reviews (ROBIS) tool [83].
SR evidence is used by decision-makers, policy makers,
and other stakeholders. They should expect consistent
and high-quality standards for reporting and conduct.
Guidelines and tools have been developed over the years
to improve RQ and MQ of SRs. Our findings suggest that
for several items in MQ or RQ tools, SR authors comply
well with the guidelines, but some items require major im-
provement. Other studies have also found that methodo-
logical and reporting quality is suboptimal [2, 84, 85]. In
addition, evidence is emerging that biases within SRs
could influence results and quality of overviews [86]. Ef-
fort should be directed towards improving the quality and
reporting of SRs, wherever possible.
Journal endorsement and implementation of the use of
reporting guidelines and critical appraisal tools during
the editorial process is one mechanism to facilitate bet-
ter quality. There is insufficient evidence to date in rela-
tion to systematic reviews but some information in
relation to trials. One recent methodological review
found insufficient evidence to determine a relationship
between endorsement and completeness of reporting: Of
101 reporting guidelines, only seven had evaluable data
from only a few evaluations each [87]. One small study
found that reporting and methodological quality (adher-
ence to both AMSTAR and PRISMA) significantly in-
creased after journal endorsement of the PRISMA
guidelines [25]. Readers may also be curious as to
whether reporting differs when examining the influence
of publication of the tools, such as a before and after
Table 2 Summary across reports of systematic reviews adhering to PRISMA reporting guidelines (N = 13) (Continued)
18. Study characteristics For each study, present characteristics for which data
were extracted (e.g., study size, PICOS, follow-up period)
and provide the citations
13 1324 1741 76
19. Risk of bias within studies Present data on risk of bias of each study and, if
available, any outcome level assessment (see item 12)
13 1199 1738 69
20. Results of individual studies For all outcomes considered (benefits or harms)
present for each study: (a) simple summary data for
each intervention group and (b) effect estimates and
confidence intervals, ideally with a forest plot
13 1399 1737 81
21. Synthesis of results Present results of each meta-analysis done, including
confidence intervals and measures of consistency
13 1150 1687 68
22. Risk of bias across studies Present results of any assessment of risk of bias across
studies (see item 15)
13 527 1736 30
23. Additional analysis Give results of additional analyses, if done (e.g.,
sensitivity or subgroup analyses, meta-regression [see
item 16])
13 631 1658 38
24. Discussion: summary of evidence Summarize the main findings including the strength of
evidence for each main outcome; consider their
relevance to key groups (e.g., healthcare providers,
users, and policy makers)
13 1085 1741 62
25. Limitations Discuss limitations at study and outcome level (e.g., risk
of bias) and at review-level (e.g., incomplete retrieval of
identified research, reporting bias)
13 1358 1741 78
26. Conclusions Provide a general interpretation of the results in the
context of other evidence and implications for future
research
13 1480 1741 85
27. Funding Describe sources of funding for the systematic review
and other support (e.g., supply of data) and role of
funders for the systematic review
13 647 1741 37
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Table 3 Summary across reports of systematic reviews adhering to QUOROM reporting guideline (N = 7)
Item assessed Item description No. of reports
reporting adherence
by item
Adhering
SRs
Total
SRs
%
Title Identify the report as a systematic review 6 133 449 30
Abstract Use a structured format 6 402 449 90
Describe the clinical question explicitly 6 341 449 76
Describe the databases (i.e., list) and other information
sources
6 335 449 75
Describe the selection criteria (i.e., population, intervention,
outcome, and study design), methods for validity
assessment, data abstraction, and study characteristics, and
quantitative data synthesis in sufficient detail to permit
replication
5 177 388 46
Describe characteristics of the RCTs included and
excluded; qualitative and quantitative findings (i.e., point
estimates and confidence intervals); and subgroup
analyses
5 180 388 46
Describe the main results 6 425 449 95
Introduction: rationale Describe the explicit clinical problem, biological rationale
for the intervention, and rationale for review
6 382 449 85
Search Describe the information sources, in detail (e.g., databases,
registers, personal files, expert informants, agencies, hand-
searching), and any restrictions (years considered,
publication status, language of publication)
5 274 388 71
Study selection Describe the inclusion and exclusion criteria (defining
population, intervention, principal outcomes, and study
design)
6 417 449 93
Data collection process Data extraction: describe the process or processes used
(e.g., completed independently, in duplicate)
6 363 449 81
Data items Describe the type of study design, participants’
characteristics, details of intervention, outcome definitions,
and how clinical heterogeneity was assessed
6 316 449 70
Risk of bias in individual studies Validity assessment: describe the criteria and process used
(e.g., masked conditions, quality assessment, and their
findings)
6 240 449 54
Synthesis of results Describe the principal measures of effect (e.g., relative risk),
method of combining results (statistical testing and
confidence intervals), handling of missing data; how
statistical heterogeneity was assessed; a rationale for any a
priori sensitivity and subgroup analyses; and any
assessment of publication bias
5 219 388 56
Results: study selection Provide a meta-analysis profile summarizing trial flow 6 40 449 9
Study characteristics Present descriptive data for each trial (e.g., age, sample
size, intervention, dose, duration, follow-up period)
6 384 449 86
Results of individual studies Report agreement on the selection and validity
assessment; present simple summary results (for each
treatment group in each trial, for each primary outcome);
present data needed to calculate effect sizes and
confidence intervals in intention-to-treat analyses (e.g., 2 ×
2 tables of counts, means and SDs, proportions)
5 213 388 55
Discussion: summary of evidence Summarize key findings; discuss clinical inferences based
on internal and external validity; interpret the results in
light of the totality of available evidence; describe
potential biases in the review process (e.g., publication
bias); and suggest a future research agenda
5 265 388 68
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publication comparison; none of the included methodo-
logical reviews assessed this. Further, in thinking about
publication and then journal endorsement as potential
interventions, we would agree with previously published
work that journal endorsement might serve as a “stron-
ger” intervention [87].
One unexplored hypothesis is whether the endorse-
ment and use of reporting tools at the protocol phase of
a SR paves the way for better reporting and methodo-
logical quality for the SR report. Review protocols allow
researchers to plan and anticipate potential issues, assess
validity of methods, and prevent arbitrary decision-
making [78, 79]. The reporting of protocols can be
guided and assessed by the Preferred Reporting Items
for Systematic Reviews and Meta-Analysis for Protocols
2015 (PRISMA-P 2015) [78, 79]. Further, Moher et al.
[2] suggested that granting agencies and journals require
full compliance with established reporting and methodo-
logical guidelines, such as a requirement to include SR
protocols with the submission of a SR.
Our review was limited exclusively to SRs included by
authors of methodological reports. Each overview had
their own selection criteria and quality thresholds; there-
fore, we did not seek out the publication of the individ-
ual SRs but relied on the data reported in each overview.
As such, there is inherent heterogeneity that may be
Table 5 Summary across reports of systematic reviews adhering to OQAQ items (N = 26)
Item assessed Item description No. of reports
reporting adherence
by item
Adhering
SRs
Total
SRs
%
1. Information sources Were the search methods used to find evidence reported? 22 1027 1387 74
2. Search Was the search strategy for evidence reasonably comprehensive? 22 754 1370 55
3. Study selection Were the criteria used for deciding which studies to include in
the overview reported?
22 1112 1387 80
4. Risk of bias in individual studies Were criteria used for assessing validity of the included studies
reported?
22 499 1367 37
5. Synthesis of results Were findings of the relevant studies combined appropriately
relative to the primary question addressed?
22 830 1387 60
6. Results: study selection Was bias in the selection of studies avoided? 22 740 1351 55
7. Synthesis of results Were methods used to combine the findings of relevant studies
(to reach a conclusion) reported?
22 1005 1387 73
8. Limitations Was the validity of all studies referred to in the text assessed
using appropriate criteria (either in selecting studies for
inclusion or in analyzing studies that are cited)?
22 898 1363 66
9. Conclusions Were the conclusions made by the author (s) supported by the
data and/or analysis reported in the overview?
22 1076 1387 78
Table 4 Summary across reports of systematic reviews meeting AMSTAR quality assessment criteria (N = 27)
Item assessed Item Description No. of reports reporting
adherence by item
Adhering
SRs
Total
SRs
%
1. Methods: Protocol and registration Was an 'a priori' design provided? 23 820 1794 46
2. Information sources Was the status of publication (i.e. grey literature)
used as an inclusion criterion?
23 1013 1794 57
3. Search Was a comprehensive literature search performed? 23 1149 1794 64
4. Data collection process Was there duplicate study selection and data extraction? 23 534 1794 30
5. Results: Study selection Was a list of studies (included and excluded) provided? 22 537 1779 30
6. Study characteristics Were the characteristics of the included studies provided? 23 1439 1794 80
7. Risk of bias within studies Was the scientific quality of the included studies
assessed and documented?
23 1200 1794 67
8. Synthesis of results Were the methods used to combine the findings
of studies appropriate?
23 1169 1794 65
9. Risk of bias across studies Was the likelihood of publication bias assessed? 23 995 1794 56
10. Limitations Was the scientific quality of the included studies used
appropriately in formulating conclusions?
23 590 1794 33
11. Funding Was the conflict of interest stated? 22 685 1779 39
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causing some of the observed variation in MQ and RQ.
In addition, we relied on how the authors assessed and
reported adherence. Variability in how strictly review au-
thors assessed adherence to items in MQ and RQ tools
could result in additional heterogeneity. Nevertheless,
this report provides some insight into the adherence to
quality assessment and reporting guideline items.
A rigorous development of tools for MQ and RQ is
important and should involve several steps and appro-
priate consideration of stakeholders and methodological
experts’ participation [88]. Despite considerable effort,
the delivery of fit-for-purpose tools may not always be
optimally achieved if items are not completely reflective
of intent. For example, it could be reasonable to note
that some MQ items in both AMSTAR and OQAQ are
written in language that reflects more of reporting than
conduct. We encourage developers to carefully consider
the wording of items. Further, any tool could potentially
be subject to content modifications as the science of
health research methodology continues to evolve.
Conclusions
In conclusion, the methodological and reporting quality
of SRs varied considerably across items in four well-
known tools. Mechanisms to improve adherence to
established reporting guidelines and methodological as-
sessment tools are needed to improve the quality of SRs.
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